Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL10511161 | 0.98 | GLA (0.39) | SMN1; SMN2KDM4EHSD17B10ALOX15TSHR | |
| SCHEMBL170215 | 0.78 | PAOX (0.46) | SMN1; SMN2KDM4ETSHRGLAKEAP1 | |
| SCHEMBL1259917 | 0.78 | — | — | |
| SCHEMBL1259599 | 0.78 | — | — | |
| SCHEMBL4392228 | 0.78 | USP2 (0.44) | SMN1; SMN2KDM4EHSD17B10ALOX15TSHR | |
| SCHEMBL6006541 | 0.77 | HPGD (0.37) | SMN1; SMN2KDM4EHSD17B10ALOX15TSHR | |
| SCHEMBL1259339 | 0.76 | SMN1; SMN2 (0.40) | SMN1; SMN2HSD17B10ALDH1A1MAPK1POLB | |
| SCHEMBL289649 | 0.75 | PAOX (0.55) | SMN1; SMN2KDM4ETSHRKEAP1ALDH1A1 | |
| SCHEMBL10502043 | 0.75 | PAOX (0.51) | SMN1; SMN2KDM4ETSHRKEAP1ALDH1A1 | |
| SCHEMBL2627646 | 0.74 | USP2 (0.34) | SMN1; SMN2KDM4EHSD17B10ALOX15TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100305093-A1 | Inhibitors of mTOR and Methods of Making and Using | EXELIXIS, INC. (US) | 2010-12-02 | — | — | US | disclosed |
| WO-2010118208-A1 | BENZOXAZEPIN-4- (5H) -YL DERIVATIVES AND THEIR USE TO TREAT CANCER | EXELIXIS, INC. (US) | 2010-10-14 | — | — | WO | disclosed |
| EP-1207161-B1 | NOVEL ISOINDOLE DERIVATIVES | BANYU PHARMA CO LTD (JP) | 2006-01-18 | — | — | EP | disclosed |
| WO-2005016883-A2 | ACRYLAMIDE DERIVATIVES AS VLA-1 INTEGRIN ANTAGONISTS AND USES THEREOF | ICOS CORPORATION (US) | 2005-02-24 | — | — | WO | disclosed |
| US-6777410-B2 | SUCH AS 9-(2-METHOXYPHENYL)-3-(1-METHYLETHYL)-(1,3)OXAZOLO-(2,3)ISOINDOLE-2,5(3H,9H)-DIONE; DIABETES AND COMPLICATIONS; OBESITY | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2004-08-17 | — | — | US | disclosed |
| US-20040053923-A1 | Novel isoindole derivatives | BANYU PHARMACEUTICAL CO., LTD. | 2004-03-18 | — | — | US | disclosed |
| US-6608098-B1 | Diabetes or obesity, 2-(4-(3-isopropyl-2,5-dioxo-2,3-dihydro-1H-pyrrolo(2,1-a) isoindol-9(5H)-yl)phenoxy)-N-propylacetamide | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2003-08-19 | — | — | US | disclosed |
| EP-1207161-A1 | NOVEL ISOINDOLE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2002-05-22 | — | — | EP | disclosed |
| EP-1157003-A1 | ACYLATED AMINOACETONITRILES AS CYSTEINE PROTEASE INHIBITORS | AstraZeneca AB (SE) | 2001-11-28 | — | — | EP | disclosed |
| EP-1155010-A1 | ACETAMIDO ACETONITRILE DERIVATIVES AS INHIBITORS OF CATHEPSIN L AND/OR CATHEPSIN S | AstraZeneca AB (SE) | 2001-11-21 | — | — | EP | disclosed |
| EP-0311322-B1 | PYRIDINE OR PYRIDAZINE DERIVATIVES AS CARDIO-PROTECTIVE AGENTS AND FOR THE TREATMENT OF ISCHEMIC DISEASE, AND PROCESS FOR THEIR PREPARATION | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1993-07-21 | — | — | EP | disclosed |
| WO-1993012796-A1 | USE OF RENIN INHIBITORS FOR THE TREATMENT OF GLAUCOMA | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1993-07-08 | — | — | WO | disclosed |
| US-5223489-A | Treatment of ypertension and heart failure | UJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1993-06-29 | — | — | US | disclosed |
| US-5142048-A | Enzyme inhibitor; carbamoyl group-containing acids | FUJISAWA PHARMACEUTICAL COMPANY, LTD. (JP) | 1992-08-25 | — | — | US | disclosed |
| US-4990507-A | Cardiotonic agents | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1991-02-05 | — | — | US | disclosed |
| EP-0228845-B1 | N-CONTAINING HETEROCYCLIC COMPOUNDS, PROCESSES FOR THE PREPARATION THEREOF AND COMPOSITION COMPRISING THE SAME | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1990-12-12 | — | — | EP | disclosed |
| US-4931453-A | CARDIOVASCULAR, HYPOTENSIVE AGENTS | FUJISAWA PHARMACEUTICAL COMPANY, LTD. (JP) | 1990-06-05 | — | — | US | disclosed |
| US-4921855-A | New Histidyl amino acid derivatives, and pharmaceutical composition comprising the same | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1990-05-01 | — | — | US | disclosed |
| US-4857527-A | HYPOTENSIVE, ANTISCHEMIC AGENT | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1989-08-15 | — | — | US | disclosed |
| US-4831030-A | FOR CEREBROVASCULAR DISEASES; HYPERTENSIVE AGENTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1989-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305093-A1 | Inhibitors of mTOR and Methods of Making and Using | MTOR, RICTOR, RPTOR | SMN1; SMN2 3454/4885KDM4E 718/4885HSD17B10 925/4885 |
| US-20040053923-A1 | Novel isoindole derivatives | GPR119, SLC5A2, SLC5A1 | SMN1; SMN2 4010/4885KDM4E 1370/4885HSD17B10 418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.